Immunotherapy in Ovarian Cancer

1. Immunological Basis

• Regulatory T cells (Tregs) that secrete IL-10 and TGF-beta, dampening cytotoxic responses
• Tumor-derived IL-6 that promotes tumor cell growth and modulates immune function
• Myeloid-derived suppressor cells (MDSCs) and immunosuppressive IDO (indoleamine 2,3-dioxygenase) production
• T-cell exhaustion driven by chronic tumor antigen exposure, which upregulates checkpoint receptors (PD-1, CTLA-4, TIM-3, LAG-3)
• Low mutational burden: High-grade serous ovarian cancer (HGSOC) has relatively few somatic mutations, meaning fewer neoantigens for T cells to recognize - a key reason why single-agent checkpoint inhibitors have been less effective than in MSI-high or TMB-high tumors

2. Types of Immunotherapy Approaches

A. Immune Checkpoint Inhibitors (ICIs)

• Anti-PD-1: Nivolumab, pembrolizumab
• Anti-PD-L1: Atezolizumab, avelumab, durvalumab
• Anti-CTLA-4: Ipilimumab
• Combination CTLA-4 + PD-1 blockade: Different, non-redundant mechanisms; combination induces ~50% tumor regression in melanoma and is being explored in ovarian cancer

B. Cytokine Therapy

C. Cancer Vaccines

• Personalized neoantigen vaccines: Early data show these can effectively mobilize antitumor T-cell immunity in ovarian cancer (Science Translational Medicine, 2018)
• CA-125 targeting vaccines: Investigated in trials but limited clinical success as monotherapy
• Dendritic cell vaccines: Phase I/II explored; synergy with checkpoint blockade is under study

D. Adoptive Cell Therapy (ACT)

• TIL therapy: Tumor-infiltrating lymphocytes expanded ex vivo and reinfused; phase I/II studies ongoing in ovarian cancer
• CAR-T cells: Targeting antigens such as folate receptor alpha (FRalpha), mesothelin, and MUC16 (CA-125); early trials underway with challenges around solid tumor penetration
• CAR-NK cells: Emerging data (2025) with CRISPR-based enhancement of NK cell potency

E. Antibody-Dependent Cellular Cytotoxicity (ADCC)

3. Major Clinical Trials and Results

First-Line Setting

Recurrent Setting

• ICI monotherapy has shown limited activity
• The SOLACE2 phase II trial (2025) tested olaparib + durvalumab + cyclophosphamide in platinum-sensitive disease

• The ARTISTRY-7 phase III trial (nemvaleukin alfa + pembrolizumab) was terminated early in March 2025 for lack of survival benefit
• FDA Approval (2025): Pembrolizumab + paclitaxel (with or without bevacizumab) was approved for platinum-resistant ovarian cancer - the first FDA approval of a checkpoint inhibitor specifically for ovarian cancer

4. The Meta-Analytic Picture (2025-2026)

• Overall, anti-PD-1/PD-L1 did not significantly improve PFS vs. control (HR 0.98; 95% CI 0.85-1.12; I² = 67%)
• No significant benefit in first-line (HR 0.93) or recurrent settings (HR 1.07)
• Non-significant trend favoring ICI + PARP inhibitor in HR-proficient patients (HR 0.77; 95% CI 0.65-0.92)

• PD-1/PD-L1 + chemotherapy and PD-1/PD-L1 + ipilimumab showed the greatest PFS/OS benefit
• ICI + chemo improved ORR most markedly (OR 3.06; 95% CI 1.42-6.60)
• PD-L1 expression is a potential predictive biomarker - PD-L1-positive patients showed better outcomes with ICI + chemotherapy

• 7 phase III trials (5,671 patients)
• Single-agent PD-L1 inhibitor trials: no significant efficacy in newly diagnosed EOC
• Triplet durvalumab + bevacizumab + olaparib: longer PFS than bevacizumab alone in non-BRCA-mutated patients
• ICI ineffective in platinum-sensitive and platinum-resistant recurrent EOC as monotherapy

5. Why Has Immunotherapy Underperformed vs. Other Cancers?

1. Low tumor mutational burden (TMB): HGSOC has fewer neoantigens than melanoma or NSCLC
2. Immunosuppressive TME: Ascites contains abundant Tregs, IL-10, TGF-beta, MDSCs
3. Low MSI/dMMR prevalence: Only ~5% of ovarian cancers are MSI-high (those benefit most from checkpoint inhibition)
4. PD-L1 is inconsistently expressed and is not a reliable single biomarker in ovarian cancer
5. T-cell exhaustion and metabolic reprogramming within the TME limit ICI reversal of exhaustion

6. Predictive Biomarkers (Emerging)

7. Emerging Strategies and Future Directions

• CTLA-4 + PD-1 dual blockade: Under investigation; dual blockade may overcome the immunosuppressive TME more effectively than single-agent
• ICI + PARP inhibitor combinations: Most promising signal to date (DUO-O); synergy proposed through PARP-trapping increasing genomic instability and immunogenicity
• ICI + anti-angiogenics (bevacizumab): Bevacizumab may "normalize" the tumor vasculature to improve T-cell infiltration
• Bispecific antibodies: Targeting TAAs (e.g., FRalpha, mesothelin) while engaging T cells
• mRNA/neoantigen vaccines + ICI: Personalized vaccine priming followed by checkpoint blockade
• IL-4 blockade: Preclinical data suggest IL-4 drives immunosuppression in ascites; dupilumab (anti-IL-4Ra) being explored to sensitize tumors to ICI
• IPROC platform trial (Canada, 2026): Ongoing multi-arm platform study specifically for platinum-resistant HGSOC, now enrolling clear cell ovarian cancer

Summary

1. Pembrolizumab + paclitaxel ± bevacizumab: FDA-approved for platinum-resistant ovarian cancer (2025)
2. Durvalumab + bevacizumab + olaparib: Most promising first-line triplet in non-BRCA-mutated HRD+ disease (DUO-O, 2026 publication), though OS data are immature
3. Monotherapy ICI: Generally ineffective in unselected ovarian cancer populations
4. Future focus: Biomarker-selected populations, combination strategies with PARP inhibitors and anti-angiogenics, and novel modalities (CAR-T, vaccines, bispecifics)

Recent evidence note: The 2026 meta-analysis (Vida et al., PMID 41763143) confirms no overall PFS benefit from anti-PD-1/PD-L1 in advanced ovarian cancer across 10 RCTs, while Ahmadi et al. 2025 (PMID 40650991) suggests combinations with chemotherapy or ipilimumab may offer benefit particularly in PD-L1-positive patients. This is a rapidly evolving field - ongoing trials will likely refine which patients benefit.

Recent Advances in the Diagnosis of Endometriosis

1. Current Gold Standard (and Its Limitations)

• Peritoneal lesions: "Powder-burn" (black/brown), red flame-like, clear vesicular, or white scarring lesions
• Endometriomas: Ovarian cysts containing thick "chocolate fluid" (hemosiderin)
• Deep infiltrating endometriosis (DIE): Lesions penetrating >5 mm below peritoneum, especially in the posterior cul-de-sac and uterosacral ligaments

Sites of endometriosis implantation across the pelvis - Berek & Novak's Gynecology

• Invasive with ~0.6-1.8/1,000 risk of major complications (bowel perforation, vascular injury)
• Surgeon experience-dependent: subtle lesions (vesicular, atypical) are easily missed
• 24% of typical-appearing lesions are histologically negative - biopsy is essential
• Does not justify routine use as a first diagnostic step
• Berek & Novak's Gynecology

2. Clinical Diagnosis (Non-Surgical)

3. Imaging: Current Status and Recent Developments

A. Transvaginal Ultrasound (TVUS) - First-Line

B. MRI - Growing Role

• Surgical mapping of complex DIE
• Detection of extrapelvic/distant endometriosis (diaphragm, bowel, ureter)
• Patients unable to tolerate TVUS
• Identifying hyperintense iron deposits in endometriotic lesions
• Less operator-dependent than TVUS due to standardized sequences

• Deep and ovarian endometriosis: sensitivity 91-93.5%, specificity 86-87.5%
• A negative eMRI does not exclude peritoneal disease (lesions <5 mm are missed)

• MRI sensitivity: 0.74 vs. TVUS sensitivity: 0.51 (p=0.04) - MRI significantly more sensitive
• Specificity comparable: MRI 0.93 vs. TVUS 0.97 (p=0.22)

C. Bowel and Urological Assessment

• Ureteral involvement is asymptomatic in up to 50% of cases
• Renal/transrectal/transvaginal US, CT urogram, or MRI are recommended to assess ureteral, bladder, and bowel involvement
• No single technique is proven superior; use what the radiologist is most experienced with

4. Biomarkers: The Frontier of Non-Invasive Diagnosis

A. CA-125 - Still Inadequate Alone

• Elevated in moderate-severe endometriosis; normal in mild disease
• Levels in moderate-severe: 13-95 U/mL (non-menstrual); wide overlap with normal (8-22 U/mL)
• Compared to laparoscopy, serum CA125 has no diagnostic value as a standalone test
• CA125 is frequently elevated with endometriomas, complicating ovarian cancer differentiation
• Berek & Novak's Gynecology

B. Neutrophil-to-Lymphocyte Ratio (NLR)

• Pooled sensitivity: 0.66, specificity: 0.63
• Positive LR: 1.79; Negative LR: 0.53
• Conclusion: NLR alone is insufficient but combinations with CA125 show more promising results

C. Proteomics-Based Biomarkers

D. MicroRNAs (miRNAs) - Most Promising Blood-Based Biomarker

• Pooled sensitivity: 0.82 (95% CI: 0.79-0.84)
• Pooled specificity: 0.79 (95% CI: 0.76-0.82)
• AUC: 0.87 - moderate-to-good diagnostic accuracy
• Multi-miRNA panels outperform single miRNAs

• miR-8: sensitivity 94.8%, specificity 91.9% - highest accuracy but high heterogeneity (I² >90%)
• miR-122: More consistent performance with narrower confidence intervals - better candidate for validation
• Current evidence limited by low GRADE certainty; independent validation cohorts needed before clinical use

E. Non-Coding RNAs (ncRNAs) Broadly

F. Endometrial Biopsy for Nerve Fibers

5. Artificial Intelligence in Endometriosis Diagnosis

• 59 studies reviewed; 6 specifically on endometriosis US
• AI models focus on classification (presence vs. absence of endometriosis) and automated segmentation
• Most models are internally validated only - external validation is lacking
• Combining eMRI and TVUS-derived AI markers may produce powerful diagnostic capability

• AI diagnostic tools combining independent eMRI and eTVUS markers are in early development
• Potential to standardize diagnosis and reduce operator dependency

6. Staging and Classification Systems

7. Special Populations: Adolescents

• Among adolescents clinically suspected of endometriosis undergoing US: 32.8% had at least one sign
• Of ultrasound-confirmed cases: 48.5% had DIE, 45.5% had endometrioma
• MRI showed signs in 49.8% of adolescent cases
• Early recognition is critical: untreated adolescent endometriosis can lead to progressive pelvic disease and fertility compromise
• The threshold for imaging should be low in young women with severe dysmenorrhea

8. Summary: Diagnostic Pathway (2024-2026 Evidence Base)

Symptoms (dysmenorrhea, CPP, dyspareunia, infertility)
         ↓
   Clinical Examination
(uterosacral nodularity, fixed uterus, cul-de-sac obliteration)
         ↓
   TVUS (first-line imaging)
   - Endometrioma: Sens 93%, Spec 96%
   - DIE nodules: Sens 79%, Spec 94%
   - Cannot exclude peritoneal disease
         ↓
   If TVUS negative but strong suspicion:
   eMRI (especially for RVS-DIE, extrapelvic, surgical planning)
   - RVS-DIE sensitivity 74% vs TVUS 51%
         ↓
   Trial of empiric hormonal therapy
   (COCs ± NSAIDs; recommended before laparoscopy if no adnexal mass)
         ↓
   Diagnostic ± Operative Laparoscopy
   (gold standard; biopsy all suspicious lesions)

• miRNA panels (AUC ~0.87) + CA125 + NLR combined scores
• Endometrial nerve fiber biopsy
• Proteomics from urine/serum
• AI-assisted eMRI/TVUS

Key Takeaways

1. Gold standard remains laparoscopy + histology - but this is being challenged by better imaging and biomarker research
2. TVUS is excellent for endometriomas (93% sensitivity) but misses peritoneal disease; eMRI is superior for rectovaginal DIE
3. No single blood test is diagnostically adequate - CA125 and NLR alone are insufficient
4. miRNA panels show the most promise among blood biomarkers (AUC 0.87); multi-miRNA combinations are superior to single markers
5. AI integration with eMRI and ultrasound is an active frontier but not yet clinically validated
6. Diagnostic delay of 6-8 years persists - empiric hormonal therapy before laparoscopy in non-adnexal-mass cases is endorsed to reduce unnecessary surgery